Literature DB >> 23993682

Facial nerve palsy after vestibular schwannoma surgery: dynamic risk-stratification based on continuous EMG-monitoring.

Julian Prell1, Christian Strauss2, Jens Rachinger2, Alex Alfieri2, Christian Scheller2, Kirsten Herfurth2, Stefan Rampp2.   

Abstract

OBJECTIVE: A-trains are a pathological pattern in intraoperative EMG-monitoring. Traintime, a parameter calculated by automated EMG-analysis, quantifies A-train activity. Its extent is associated with the degree of postoperative facial nerve palsy. However, false positive results have been observed. A systematic flaw in automated analysis was hypothesized.
METHODS: Facial nerve EMG-data from 79 patients undergoing vestibular schwannoma surgery were analyzed visually. Automated traintime was compared with these results. The progressive risk for postoperative paresis was calculated with respect to traintime (visual and automated).
RESULTS: Automated analysis identified a small (1.46%), but highly representative fraction of overall A-train activity: Pearson's correlation coefficient between both values was 0.944 (p<0.001). Both were correlated with clinical outcome in a highly significant way (p<0.001) with Spearman's Rho 0.592 (automated) and 0.563 (visual). Progressive risk development was visualized as an inverse sigmoid curve with traintime on a logarithmic scale.
CONCLUSIONS: Automated traintime is a representative and reliable expression for overall A-train activity. As risk-development is complex, rigid thresholds are problematic. SIGNIFICANCE: Individual risk for postoperative palsy can be estimated on the basis of the calculated curve presented. This approach is of higher practical value than a rigid (and low) threshold.
Copyright © 2013 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  A-train; EMG; Facial nerve; Neurophysiologic monitoring; Traintime; Vestibular schwannoma

Mesh:

Year:  2013        PMID: 23993682     DOI: 10.1016/j.clinph.2013.07.015

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  6 in total

1.  Mitochondrial Cyclophilin D as a Potential Therapeutic Target for Ischemia-Induced Facial Palsy in Rats.

Authors:  Huizhen Chen; Chnagtao Liu; Jie Yin; Zhen Chen; Jinwang Xu; Duanlei Wang; Jiaqiu Zhu; Ziyuan Zhang; Yong Sun; Aimin Li
Journal:  Cell Mol Neurobiol       Date:  2015-03-29       Impact factor: 5.046

Review 2.  [Intraoperative monitoring of the facial nerve : Vestibular schwannoma surgery].

Authors:  J Prell; C Strauss; S K Plontke; S Rampp
Journal:  HNO       Date:  2017-05       Impact factor: 1.284

3.  The utility of "low current" stimulation threshold of intraoperative electromyography monitoring in predicting facial nerve function outcome after vestibular schwannoma surgery: a prospective cohort study of 103 large tumors.

Authors:  Xiang Huang; Junwei Ren; Jian Xu; Ming Xu; Danqi Chen; Mingyu Chen; Kaiyuan Ji; Hai Wang; Huiyu Chen; Lijie Cao; Yilin Shao; Ping Zhong; Richard Ballena; Liangfu Zhou; Ying Mao
Journal:  J Neurooncol       Date:  2018-02-23       Impact factor: 4.130

4.  Continuous dynamic mapping to avoid accidental injury of the facial nerve during surgery for large vestibular schwannomas.

Authors:  Kathleen Seidel; Matthias S Biner; Irena Zubak; Jonathan Rychen; Jürgen Beck; Andreas Raabe
Journal:  Neurosurg Rev       Date:  2018-10-26       Impact factor: 3.042

5.  Design and Evaluation of a Custom-Made Electromyographic Biofeedback System for Facial Rehabilitation.

Authors:  Kathrin Machetanz; Florian Grimm; Ruth Schäfer; Leonidas Trakolis; Helene Hurth; Patrick Haas; Alireza Gharabaghi; Marcos Tatagiba; Georgios Naros
Journal:  Front Neurosci       Date:  2022-03-04       Impact factor: 4.677

6.  TcMEP threshold change is superior to A-train detection when predicting facial nerve outcome in CPA tumour surgery.

Authors:  Tom Hendriks; Henricus P M Kunst; Maarten Huppelschoten; Jonne Doorduin; Mark Ter Laan
Journal:  Acta Neurochir (Wien)       Date:  2020-03-07       Impact factor: 2.216

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.